The Cardiomyopathy and Cardio-Oncology Symposium is designed to provide a state-of-the-art, comprehensive curriculum that addresses important clinical topics relevant to cardiomyopathy and the cardiovascular health of cancer patients and survivors. Cardio-oncology is an important and emerging field of medicine resulting from new or unexpected cardiovascular toxicities many cancer survivors are now experiencing because of their cancer treatments. In addition, cardiac amyloidosis is a burgeoning disease with exciting new treatments. Nationally recognized faculty in the fields of cardiology and oncology will discuss challenging topics related to common cardiomyopathies as well as current best practices for diagnosing, treating and managing patients. The goal of the conference is for participants to return to their practice equipped with the latest evidence base and practical information to improve patient care.
Educational Objectives
After attending this live activity, participants should be able to:
• Evaluate current and emerging treatment options for cardiac amyloidosis.
• Discuss diagnosis and treatment considerations for patients with cardiac sarcoidosis.
• Assess the importance of genetic testing and treatment for genetic cardiomyopathies including hypertrophic cardiomyopathy.
• Analyze best practices in the multidisciplinary monitoring and management of cardiac toxicity in patients undergoing cancer therapy.
• Employ management strategies for venous thromboembolism and other cardiovascular complications that may occur in patients with cancer.
• Demonstrate the importance of ongoing cardiac disease monitoring in cancer survivors.
The Scripps 7th Annual Cardiomyopathy and Cardio-Oncology Symposium 2024 is designed for a wide range of healthcare professionals interested in cardiomyopathy and cardio-oncology. The target audience includes:
- Physicians
- Cardiologists
- Oncologists
- Nurses
- Nurse practitioners
- Physician assistants
- Pharmacists
- Allied health professionals
This symposium focuses on the cardiovascular health of cancer patients and survivors, addressing important clinical topics and best practices for diagnosing, treating, and managing patients with cardiomyopathies and cardiovascular toxicities related to cancer treatments
+ Topics:
brochure_cmp24.pdf
SESSION I Cancer-Associated Thrombosis.mp4
SESSION I Cardiotoxicity Anthracyclines.mp4
SESSION I Cardiotoxicity Immunotherapy.mp4
SESSION I Comprehensive Management of PE.mp4
SESSION I Diagnosis of Sarcoid.mp4
SESSION I HCM-Diagnosis and Treatment.mp4
SESSION I Imaging of Sarcoid.mp4
SESSION I MRI Imaging in Cardiotoxicity.mp4
SESSION I Panel Discussion Q&A.mp4
SESSION I Treatment of Sarcoid.mp4
SESSION II Cardiac Amyloidosis Mimickers.mp4
SESSION II MRI Imaging in Amyloid.mp4
SESSION II Nuclear Imaging in Amyloid.mp4
SESSION II Panel Discussion Q&A.mp4
SESSION II What and When to Biopsy.mp4
SESSION II When is MGUS Clinically Significant.mp4
SESSION II When to Suspect Amyloidosis.mp4
SESSION III AL Amyloidosis Current Treatments.mp4
SESSION III Current Treatment of ATTR Silencers.mp4
SESSION III Current Treatment of ATTR Stabilizers.mp4
SESSION III Emerging ATTR Treatments.mp4
SESSION III Panel Discussion Q&A.mp4
SESSION III Racial and Geographic Disparities in Amyloid.mp4
SESSION III Staging in Amyloid.mp4
SESSION IV Carpal Tunnel in Amyloid.mp4
SESSION IV Managing GI Issues in Amyloidosis.mp4
SESSION IV Neuropathy and Dysautonomia in Amyloid.mp4
SESSION IV Panel Discussion Q&A.mp4
SESSION IV Transplant in Amyloidosis.mp4